srf617
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2020 (NCT04336098)
Timeline
Indications
Mechanism of action
ENTPD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05177770 | Phase 2 | Jan 17, 2022 | Arcus Biosciences, Inc., Surface Oncology |
| NCT04336098 | Phase 1 | Mar 16, 2020 | Surface Oncology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Surface Oncology | For profit | 2 | 2 | 2 | 2020 |
| Arcus Biosciences, Inc. | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1